% | $
Quotes you view appear here for quick access.

Trius Therapeutics, AŞ Message Board

  • tigrdog3 tigrdog3 Mar 13, 2013 9:39 AM Flag

    Piper Jaffray

    March 13, 2013
    07:00 EDT TSRX Trius Therapeutics should be bought ahead of data, says Piper Jaffray
    Piper Jaffray recommends buying shares of Trius Therapeutics ahead of the ESTABLISH-2 study data later this month. The firm expects positive data to drive Trius shares higher and views the company as a potential acquisition candidate. Piper keeps an Overweight rating on the stock with an $11 price target.